

Diagnostic Specialist

First Quarter
Report

2009

DiaSorin

The Diagnostic Specialist



**INTERIM REPORT ON OPERATIONS
FIRST QUARTER OF 2009**

Diasorin S.p.A.

Via Crescentino (no building No.) - 13040 Saluggia (VC) Tax I.D. and Vercelli Company Register No. 13144290155

Contents

Board of Directors, Board of Statutory Auditors and Independent Auditors	p. 3
Consolidated financial highlights	p. 4
Report on operations	p. 5
1. Review of the Group's operating performance and financial position	p. 5
2. Transactions with related parties	p. 15
3. Listing requirements set forth in Article 36, Letters a), b) and c), of the Market Regulations	p. 16
4. Significant events occurring after March 31, 2009 and business outlook	p. 17
Consolidated financial statements of the Diasorin Group at March 31, 2009 and March 31, 2008	p. 18
Consolidated Income Statement	p. 19
Consolidated Balance Sheet	p. 20
Cash Flow Statement	p. 22
Statement of changes in consolidated shareholders' equity	p. 23
Notes to the consolidated financial statements at March 31, 2009	p. 24
Description and main changes	p. 27
Annex I: List of Equity Investments	p. 32

Board of Directors, Board of Statutory Auditors and Independent Auditors

Board of Directors (elected on March 26, 2007)

Chairman	Gustavo Denegri
Executive Deputy Chairman	Antonio Boniolo
Chief Executive Officer	Carlo Rosa ⁽¹⁾
Directors	Giuseppe Alessandria ^{(2) (3)}
	Chen Menachem Even
	Enrico Mario Amo
	Ezio Garibaldi ⁽²⁾
	Michele Denegri
	Franco Moscetti ⁽²⁾

Board of Statutory Auditors

Chairman	Luigi Martino
Statutory Auditors	Bruno Marchina
	Vittorio Moro
Alternates	Alessandro Aimo Boot
	Maria Carla Bottini

Committees

Internal Control Committee	Ezio Garibaldi (Chairman)
	Franco Moscetti
	Enrico Mario Amo
Compensation Committee	Giuseppe Alessandria (Chairman)
	Ezio Garibaldi
	Michele Denegri
Nominating Committee	Franco Moscetti (Chairman)
	Giuseppe Alessandria
	Michele Denegri

Independent Auditors	Deloitte & Touche S.p.A.
-----------------------------	--------------------------

⁽¹⁾ General Manager

⁽²⁾ Independent Director

⁽³⁾ Lead Independent Director

Consolidated financial highlights

Income statement <i>(in thousands of euros)</i>	First quarter 2009	First quarter 2008	First quarter 2008 proforma
Net revenues	71,369	56,638	59,120
Gross profit	49,887	36,584	38,334
EBITDA ⁽¹⁾	28,376	19,191	21,294
Operating result (EBIT)	24,405	15,682	16,325
Net profit for the period	13,161	10,141	10,706

Balance sheet <i>(in thousands of euros)</i>	3/31/2009	12/31/2008
Net invested capital	182,037	173,910
Net borrowings	12,107	19,763
Shareholders' equity	169,930	154,147

Cash flow statement <i>(in thousands of euros)</i>	First quarter 2009	First quarter 2008
Net cash flow for the period	8,411	4,727
Free cash flow ⁽²⁾	9,658	6,088

Personnel and Investments	First quarter 2009	First quarter 2008
Number of employees at March 31	1,135	942
Capital expenditures <i>(in thousands of euros)</i>	9,106	3,034

Key performance indicators	First quarter 2009	First quarter 2008
EBITDA/Net revenues	39.8%	33.9%
Profit before taxes/Net revenues	29.1%	28.7%
Net borrowings/Shareholders' equity	0.07	0.13
Gearing ⁽³⁾	6.7%	11.4%

⁽¹⁾ The Board of Directors defines EBITDA as the "operating result (EBIT)" before amortization of intangibles and depreciation of property, plant and equipment.

⁽²⁾ Free cash flow is the cash flow from operating activities, counting utilizations for capital expenditures but excluding interest payments.

⁽³⁾ Gearing is the ratio of net borrowings to total sources of funds.

Report on operations

1. Review of the Group's operating performance and financial position

1.1. Foreword

This Interim Report on Operations at March 31, 2009 (hereinafter also referred to as Quarterly Report) was prepared in accordance with Article 154 *ter* of Legislative Decree No. 58/1998), as amended, and with the Issuers' Regulations published by the Consob.

This Quarterly Report is consistent with the requirements of the International Financial Reporting Standards (IFRS), as published by the International Accounting Standards Board ("IASB"), and was prepared in accordance with IAS 34 – Interim Financial Reporting.

In the third quarter of 2008, Diasorin entered into an agreement to buy the Biotrin Group, which is based in Ireland. As a result of this transaction, the Group consolidates Biotrin on a line-by-line basis as of the date of acquisition (July 9, 2008). In order to offer a clearer presentation of the indicators of operating performance, this Report on Operations also provides a comparison with a pro forma 2008 income statement, restated to reflect the contribution of the Biotrin Group in the first quarter of 2008 and make the financial data comparable with those reported in the same period in 2009.

This Interim Report on Operations was not audited.

1.2. The foreign exchange market

During the first quarter of 2009, the euro lost considerable value versus the U.S. dollar, compared with the same period in 2008, but appreciated vis-à-vis the other main reporting currencies of the Group.


Specifically regarding the U.S. dollar, the average exchange rate was 1.3029 U.S. dollars for one euro in the first quarter of 2009, down from 1.4976 U.S. dollars for one euro in the same period last year.

The table below provides a comparison of end-of-period exchange rates (source: Italian Foreign Exchange Bureau):

Currency	First quarter 2009		First quarter 2008	
	Average	End-of-period	Average	End-of-period
U.S. dollar	1.3029	1.3308	1.4976	1.5812
Brazilian real	3.0168	3.0767	2.6012	2.7554
British pound	0.9088	0.9308	0.7570	0.7958
Swedish kronor	10.9410	10.9400	9.3996	9.3970
Czech koruna	27.6008	27.3880	25.5639	25.3350
Canadian dollar	1.6223	1.6685	1.5022	1.6226
Mexican peso	18.7267	18.7623	16.1862	16.8983
Israeli shekel	5.2870	5.5715	5.4322	5.6200

1.3. Operating performance in the first quarter of 2009

The positive results reported in the first quarter of 2009 represent a further increase on the strong growth achieved by the Diasorin Group in 2008 and provide confirmation that all key profitability indicators are continuing to improve.




Revenues grew to 71,369,000 euros in the first quarter of 2009, for a gain of 26.0% compared with the same period last year. It is worth noting that the revenues generated by Biotrin Group products account for a portion of the increase over the amount reported at March 31, 2008 (contribution of 5.2 percentage points). In addition, the Group's positive performance in the first three months of 2009 benefited from the renewed strength of the U.S. dollar versus the euros, offset only in part by weaker exchange rates for all of the other currencies used by the Group (fluctuations in foreign exchange parities contributed 3.8 percentage points to the revenues increase).


An analysis of revenues in terms of technology shows that a key factor driving revenue growth is rising demand for CLIA products. Sales of these products were up 34.8% in the first quarter of 2009, due to a steady expansion of the installed base of LIAISON systems, which had grown to about 2,640 units at the end of March, after the addition of about 130 units in the first three months of 2009. Sales of CLIA technology reagent accounted for 60.6% of total revenues in the first quarter of 2009.

A breakdown of revenues by geographic region shows sustained growth rates in virtually all regions, with the biggest gains reported in the United States (+73.4%) and the rest of the world (+26.6%), which consists mostly of emerging countries.

The beneficial impact of an increase in revenues, combined with the effect of the actions taken to control and reduce industrial and operating costs, produced important gains in the profitability indicators in the first quarter of 2009, compared with the same period last year. Consolidated EBIT rose from 15,682,000 euros in 2008 to 24,405,000 euros in 2009, for a year-over-year increase of 55.6%.



EBITDA grew at a rate of 47.9 % in the first three months of 2009, rising to 28,376,000 euros, compared with 19,191,000 euros at March 31, 2008.



Lastly, the Group earned a net profit of 13,161,000 euros in the first quarter of 2009, up from 10,141,000 euros in the same period a year ago, for a year-over-year growth of 29.8%.

A significant development that occurred during the first three months of 2009 was the start of direct sales in the Czech Republic and Slovakia through a subsidiary established by the Group in the Czech Republic in the fourth quarter of 2009. A consolidated income statement for the quarters ended March 31, 2009 and 2008 is provided below.

CONSOLIDATED INCOME STATEMENT

<i>(in thousands of euros)</i>	First quarter		
	2009 ^(*)	2008 ^(*)	2008 pro forma ^(*)
Net revenues	71,369	56,638	59,120
Cost of sales	(21,482)	(20,054)	(20,786)
Gross profit	49,887	36,584	38,334
	69.9%	64.6%	64.8%
Sales and marketing expenses	(13,499)	(11,267)	(11,662)
Research and development costs	(3,783)	(3,089)	(3,369)
General and administrative expenses	(7,782)	(6,358)	(6,786)
Total operating expenses	(25,064)	(20,714)	(21,817)
	(35.1%)	(36.6%)	(36.9%)
Other operating income (expenses)	(418)	(188)	(192)
Operating result (EBIT)	24,405	15,682	16,325
	34.2%	27.7%	27.6%
Net financial income/(expense)	(3,640)	579	501
Result before taxes	20,765	16,261	16,826
Income taxes	(7,604)	(6,120)	(6,120)
Net result	13,161	10,141	10,706
Basic earnings per share	0.24	0.18	0.19
Diluted earnings per share	0.24	0.18	0.19
EBITDA ^(†)	28,376	19,191	21,294
	39.8%	33.9%	36.0%

^(*) Unaudited data.

^(†) The Board of Directors defines EBITDA as the "operating result (EBIT)" before amortization of intangibles and depreciation of property, plant and equipment.


1.3.1. Net revenues

1.3.1.1. Analysis of revenues by geographic region


The table below provides a breakdown of the consolidated revenues of the Diasorin Group by geographic region of destination:

<i>(in thousands of euros)</i>	First quarter 2009	First quarter 2008	% change
Italy	14,380	13,561	6.0%
Rest of Europe	23,107	21,008	10.0%
North America (United States and Canada)	21,996	12,683	73.4%
Rest of the world	11,886	9,386	26.6%
Total	71,369	56,638	26.0%

1st quarter 2009



1st quarter 2008



Italy

Revenues booked in Italy in the first quarter of 2009 totaled 14,380,000 euros, or 6 % more than in the same period last year. The overall rate of increase was affected by some weakness early in the quarter, caused by the delayed start of some public-sector orders, but the shortfall was made up during the second half of the period.

Sales of products based on CLIA technology grew to account for 75.6% of the overall revenues.

The revenues generated in Italy during the first three months of 2009 were equal to 20.1% of the consolidated revenues of the Diasorin Group in the same period.

Rest of Europe

The aggregate revenues booked in the other European market increased from 21,008,000 euros in the first quarter of 2008 to 23,107,000 euros in the same period this year, for a year-over-year gain of 10 percentage points.

The best sales gains were reported by Group subsidiaries in France (+31.6%), Sweden (+55.2% at current exchange rates, +83.5 % at constant March 2008 exchange rates) and Belgium (+11.8%).

The exchange rate for the British pound weakened significantly, compared with the first quarter of 2008, with a negative impact of 18 percentage points on revenue growth in the UK. Stated at constant exchange rates, UK revenues are 8.1% higher than the previous year.

Lastly, in the markets served through distributors, revenues were down in Russia and Turkey, due to the current economic crisis, but increased significantly in China, thanks to the expansion of the installed base of LIAISON systems.

As a result of the improvements described above, the contribution provided by the rest of Europe to the Group's consolidated revenues was equal to 32.4%.

North America

The North American market continues to be the main engine driving the Group's revenue growth. First quarter revenues increased by 73.4 percentage points (at current exchange rates), rising from 12,683,000 euros in 2008 to 21,996,000 euros in 2009. When they are stated in U.S. dollars to eliminate the impact of fluctuations in exchange rates, revenues show a gain of 51%.

It is also worth noting that the revenue growth achieved in North America reflects in part the contribution provided by sales of Biotrin products, which account for 10.8 percentage points of the overall increase at current exchange rates, including 1.4 percentage points attributable to favorable exchange rates.

Diasorin's success in the American market is due to a significant extent to growing demand for tests to determine Vitamin D level, as the use of this test is becoming increasingly widespread, thanks to the results of clinical trials that have broadened its use to oncology and to assess the risk of the onset of cardiovascular diseases. The Company has a position of absolute leadership in the Vitamin D market.

In the first three months of 2009, sales in the North American market contributed 30.8% of the Group's total revenues.

Rest of the world

The revenues booked in the remaining Group markets increased to 11,886,000 euros in the first quarter of 2009, for a gain of 26.6 percentage points compared with revenues of 9,386,000 euros in the same period last year.

The best performance were reported by the branches recently established in Israel and Mexico.

The Israeli subsidiary increased revenues by 127 percentage points compared with the first quarter of 2008, owing in part to the impact of a favorable exchange rate (6.1 percentage points) and the acquisition of the business operations of a local distributor (53.9 percentage points). The revenues of the Mexican subsidiary grew by 28.6 percentage points compared with the first three months of 2008. However, the growth is equal to 48.8 percentage points with data stated in the local currency.

In the regions where the Group operates through independent distributors, first quarter revenues increased by 22.5 percentage points in 2009, with the biggest increase recorded in Australia.

1.3.1.2. Analysis of revenues by technology


Concurrently with its geographic expansion, the Group continued to increase the revenues generated by its closed LIAISON technology platform.

The table below shows the percentage of consolidated revenues contributed by each technology in the first quarter of 2009 and 2008.


	First quarter 2009	First quarter 2008
RIA	8.5	10.2
ELISA	22.4	21.8
CLIA	60.6	56.6
Equipment and other revenues	8.5	11.4
Total	100.0	100.0

In the first quarter of 2009, the revenues generated by LIAISON products increased by 34.8 percentage points, compared with the same period in 2008.

1st quarter 2009



1st quarter 2008



Revenues contributed by sales of products based on CLIA technology accounted for 60.6% of total Group revenues in the first quarter of 2009. At March 31, 2009, about 2,640 automated LIAISON analyzers were installed at facilities operated by direct and indirect customers of the Group.

The basic stability of the percentage of consolidated revenues generated by sales of ELISA products is explained by the contribution provided by sales of Biotrin products.

1.3.2. Operating performance

The data for the first quarter of 2009 show a further increase in gross profit, compared with the previous year. The gross profit grew to 49,887,000 euros, or 36.4% more than in the corresponding period a year ago.

The ratio of gross profit to revenues improved from 64.6% in the first quarter of 2008 to 69.9% in the first three months of 2009.

The rising percentage of total revenues contributed by sales of CLIA technology products, which generate higher margins than products based on RIA and ELISA technologies, continue to drive the improvement in operating performance. Other positive factors include the growing percentage of revenues represented by sales of the LIAISON VITAMIN D – Total test, which generate event better margin than other products in the LIAISON portfolio, and a reduction in the percentage of total revenues generated by equipment sales.

The improvement in the Group's profitability also reflects the positive impact of the more favorable U.S. dollar/euro exchange rate mentioned earlier in this Report and a reduction in the impact of depreciation expense, made possible by maximizing sales on the installed base.

Lastly, the economies of scale achieved during a period when manufacturing facilities operated at a higher than usual utilization rate to build up the inventory of strategic semifinished components also contributed to the improvement in gross profit.

Operating expenses totaled 25,064,000 euros, or 21% more than in the first quarter of 2008. This increase is due in part to an expansion of the Group's business operations, following the acquisition of the Biotrin Group and the establishment of new sales branches in the Czech Republic, Austria and Canada. In any case, while operating expenses increased in absolute terms, their ratio to revenues decreased by 1.5 percentage points, falling from 36.6 in the first three months of 2008 to 35.1% in the same period this year.

Research and development costs that are charged in full to income when incurred increased by 22.5% compared with the first quarter of 2008, rising to 3,783,000 euros, an amount equal to 5.3% of revenues. In addition, costs totaling 431,000 euros were capitalized during the first three months of 2009.

Consolidated EBIT, which amounted to 24,405,000 euros in the first quarter of 2009, were equal to 34.2% of revenues (27.7% in the in the first three months of 2008). Over the same period, EBITDA totaled 28,376,000 euros, or 39.8% of revenues. At March 31, 2008, EBITDA were equal to 33.9% of revenues.

1.3.3. Financial income and expense

In the first quarter of 2009, net financial expense amounted to 3,640,000 euros, as against net financial income of 579,000 euros in the same period last year. This difference in quarterly performance is due in its entirety to the impact of fluctuations in exchange rates on the Group's borrowings in foreign currency.

The currency translation losses recognized on the Group's foreign currency exposure (2,760,000 euros in the first quarter of 2009) are related mainly to indebtedness denominated in U.S. dollars contracted by the Parent Company in connection with the Biotrin acquisition. While currency translation differences have an accounting impact on the net profit for the period, the corresponding charge is recognized for valuation purposes and does not entail a cash outlay. This is because the Group's financial policy is designed to match the strong cash flow in U.S. dollars generated by the expansion of the U.S. operations with indebtedness in the same currency, thus balancing cash inflows and outflows.

Interest and other financial expense includes 243,000 euros in interest on borrowings (224,000 euros in the first quarter of 2008), 324,000 euros in fees on factoring transactions (505,000 euros in the first quarter of 2008) and 216,000 euros in financial expense on employee benefit plans (223,000 euros in the first quarter of 2008).

1.3.4. Result before taxes and net result

The first quarter of 2009 ended with a result before taxes of 20,765,000 euros and a tax liability of 7,604,000 euros. The pretax amount was higher than in the same period in 2008, when it totaled 16,261,000 euros, subject to a tax liability of 6,120,000 euros.

The tax rate for the quarter was 36.6% (37.6% in the first quarter of 2008).

The consolidated net result for the first quarter of 2009 was thus equal to 13,161,000 euros, for a gain of 29.8% compared with the 10,141,000 euros earned in the same quarter a year ago.

Basic earnings per share amounted to 0.24 euros in the first quarter of 2009, up from 0.18 euros in the same period the previous year. The current stock option plan did not have a dilutive effect on quarterly earnings per share.

1.4. Analysis of Consolidated Cash Flow

A table showing a condensed consolidated cash flow statement, followed by a review of the main statement items and the changes that occurred compared with the previous period, is provided below.

CASH FLOW STATEMENT

<i>(in thousands of euros)</i>	First quarter 2009 ^(*)	First quarter 2008 ^(*)
Cash and cash equivalents at beginning of period	16,790	8,367
Net cash from operating activities	18,062	8,161
Cash used for investing activities	(8,838)	(2,684)
Cash used for financing activities	(813)	(750)
Net change in cash and cash equivalents	8,411	4,727
Cash and cash equivalents at end of period	25,201	13,094

^(*) Unaudited data.

The cash flow from operating activities grew from 8,161,000 euros in the first quarter of 2008 to 18,062,000 euros in the same period this year. This increase reflects an improvement in the income stream (net result plus depreciation and amortization, additions to provisions and other non-cash items), which more than offset a rise in working capital that was in line with that of the previous year. More specifically, trade receivables were up compared with December 31, 2008 consistent with a rise in revenues, but the rate of increase was proportionately smaller than the growth in revenues. Inventories were also up reflecting the impact of an increase in sales and of a period of a higher than usual level of manufacturing activity carried out to build up the inventory of strategic semifinished components.

The cash used for investing activities amounted to 8,838,000 euros, including about 3 million euros invested to gain distribution rights in markets targeted by the Group for geographic expansion, the Czech Republic in particular. Capital expenditures for medical equipment totaled 3,235,000 euros, up from 1,798,000 euros in the first three months of 2008.

In the first quarter of 2009, the net change in cash and cash equivalents was positive by 8,411,000 euros, compared with a positive change of 4,727,000 euros in the same period last year.

At March 31, 2009, the cash and cash equivalents held by the Group totaled 25,201,000 euros, up from 16,790,000 euros at the end of 2008.

1.5. Net Borrowings

<i>(in thousands of euros)</i>	At March 31, 2009	At December 31, 2008
Cash and cash equivalents	(25,201)	(16,790)
Liquid assets (a)	(25,201)	(16,790)
Current bank debt	3,110	3,442
Other current financial obligations	1,759	1,873
Current indebtedness (b)	4,869	5,315
Net current indebtedness (c)=(a)+(b)	(20,332)	(11,475)
Non-current bank debt	30,957	29,352
Other non-current financial obligations	1,482	1,886
Non-current indebtedness (d)	32,439	31,238
Net borrowings (e)=(c)+(d)	12,107	19,763

Other information

The Group had 1,135 employees at March 31, 2009 (942 employees at March 31, 2008).

2. Transactions with related parties

In the normal course of business, Diasorin S.p.A. engages on a regular basis in commercial and financial transactions with its subsidiaries, which are also Group companies. These transactions, which are executed on standard market terms, consist of the supply of goods and services, including administrative, information technology, personnel management, technical support and consulting services, which produce receivables and payables at the end of the year, and financing and cash management transactions, which produce income and expenses.

These transactions are eliminated in the consolidation process and, consequently, are not discussed in this section of the Report.

At March 31, 20089 the following transactions had been executed with Diasorin LTD, an unconsolidated Chinese subsidiary:

- liabilities of 147,000 euros
- costs totaling 369,000 euros for sales and technical support provided to local distributors.

The Group provides additional benefits to qualified employees of Diasorin S.p.A. and other Group companies by means of a stock option plan. In the first three months of 2009, the impact of this plan on the income statement totaled 178,000 euros (132,000 euros in 2008).

The compensation payable to senior managers and eligible employees (key management) is consistent with standard market terms for compensation offered to employees with a similar status.

Employees are also awarded incentive payments tied to the achievement of corporate or personal targets and bonuses predicated on the achievement of a predetermined length of service.

3. Listing requirements set forth in Article 36, Letters a), b) and c), of the Market Regulations

With regard to compliance with the requirements for the listing of shares introduced by Article 36 of the regulations adopted by the Consob with Resolution No. 16191 of October 29, 2007, the issuer Diasorin S.p.A., in its capacity as the controlling company of subsidiaries among which there are companies that, while established in accordance with and governed by the laws of countries that are not members of the European Union, are materially relevant for the purpose of complying with the provisions of Title VI, Chapter II, of the regulations adopted by the Consob with Resolution No. 11971 of 1999, as amended:

- a) Makes available to the public the accounting schedules provided by its subsidiaries in connection with the preparation of the consolidated financial statements. As a minimum, these schedules include a balance sheet and an income statement, as already required to comply with the provisions of Article 2429 of the Italian Civil Code. The accounting schedules are made available to the public in the manner required by the provisions of Part III, Title II, Section V, of the regulations adopted by the Consob with Resolution No. 11971 of 1999, as amended.
- b) Its subsidiaries provide it on a regular basis, but always promptly when changes in substance or form occur, with copies of their Bylaws and documents setting forth the composition and powers of their governance bodies.
- c) It ensures that its subsidiaries:
 - i) provide the Parent Company's Independent Auditors with the information they need to audit the Parent Company's annual and interim financial statements;
 - ii) adopt an adequate accounting system that enables them to deliver on a regular basis to the Group's management and the Parent Company's Independent Auditors the income statement, balance sheet and financial position data needed to prepare the consolidated financial statements.

4. Significant events occurring after March 31, 2009 and business outlook

On April 30, 2009, Interbanca SpA disbursed to the Group's Parent Company the balance of a facility agreed to on July 7, 2008, in the amount of 6,897,000 euros. This amount is being used to refinance recently completed geographic expansion activities and fund future projects in this area.

No other significant events requiring disclosure occurred after the end of the quarter and the Diasorin Group continued to achieve positive operating results after March 31, 2009.

In light of the strong rate of revenue growth, the relative stability of the euro/U.S. dollar exchange rate and the continuing success of the LIAISON Vitamin D- Total test in the North American market, the Group believes that it should revise upward the guidance provided earlier in the year and project revenue growth of more than 15% for the current year, with all profitability indicators showing proportionately larger rates of increase.

Saluggia, May 15, 2009

The Board of Directors
by Carlo Rosa
Chairman of the Board of Directors

**Consolidated financial statements of the Diasorin Group
at March 31, 2009 and March 31, 2008**

CONSOLIDATED INCOME STATEMENT

<i>(in thousands of euros)</i>	Notes	First quarter 2009 ^(*)	First quarter 2008 ^(*)
Net revenues	(1)	71,369	56,638
Cost of sales	(2)	(21,482)	(20,054)
Gross Profit		49,887	36,584
Sales and marketing expenses	(3)	(13,499)	(11,267)
Research and development costs	(4)	(3,783)	(3,089)
General and administrative expenses	(5)	(7,782)	(6,358)
Other operating income (expenses)	(6)	(418)	(188)
Operating result (EBIT)		24,405	15,682
Net financial income (expense)	(7)	(3,640)	579
Result before taxes		20,765	16,261
Income taxes	(8)	(7,604)	(6,120)
Net result		13,161	10,141
Basic earnings per share	(9)	0.24	0.18
Diluted earnings per share	(9)	0.24	0.18

^(*) Unaudited data.

CONSOLIDATED BALANCE SHEET

<i>(in thousands of euros)</i>	Notes	3/31/2009 ^(*)	12/31/2008
ASSETS			
<i>Non-current assets</i>			
Property, plant and equipment	(10)	37,193	35,446
Goodwill	(11)	59,892	59,892
Other intangibles	(11)	37,002	33,413
Equity investments		123	276
Deferred-tax assets		9,996	9,844
Other non-current assets		278	273
Total non-current assets		144,484	139,144
<i>Current assets</i>			
Inventories	(12)	46,002	41,443
Trade receivables	(13)	68,330	62,708
Other current assets		4,943	4,632
Cash and cash equivalents		25,201	16,790
Total current assets		144,476	125,573
TOTAL ASSETS		288,960	264,717

^(*) Unaudited data.

CONSOLIDATED BALANCE SHEET

<i>(in thousands of euros)</i>	Notes	3/31/2009 ^(*)	12/31/2008
LIABILITIES AND SHAREHOLDERS' EQUITY			
<i>Shareholders' equity</i>			
Share capital	(14)	55,000	55,000
Additional paid-in capital	(14)	5,925	5,925
Statutory reserve	(14)	1,140	1,140
Other reserves	(14)	1,871	(751)
Retained earnings (Accumulated deficit)	(14)	92,833	55,374
Net result for the period	(14)	13,161	37,459
Total shareholders' equity		169,930	154,147
<i>Non-current liabilities</i>			
Non-current borrowings	(15)	32,439	31,238
Provisions for employee severance indemnities and other employee benefits	(16)	19,461	19,306
Deferred-tax liabilities		1,874	1,997
Other non-current liabilities	(17)	2,113	1,594
Total non-current liabilities		55,887	54,135
<i>Current liabilities</i>			
Trade payables		30,852	28,780
Other current liabilities		15,725	16,166
Income taxes payable		11,697	6,174
Current portion of long-term debt	(15)	4,869	5,315
Total current liabilities		63,143	56,435
Total liabilities		119,030	110,570
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY		288,960	264,717

^(*) Unaudited data.

CASH FLOW STATEMENT

<i>(in thousands of euros)</i>	First quarter 2009 ^(*)	First quarter 2008 ^(*)
Cash flow from operating activities		
Net result for the period	13,161	10,141
Adjustments for:		
- Income taxes	7,604	6,120
- Depreciation and amortization	3,971	3,509
- Financial expense	3,640	(579)
- Additions to/(Utilizations of) provisions for risks	437	38
- (Gains)/Losses on sales of non-current assets	-	14
- Contributions to/(Reversals of) provisions for employee severance indemnities and other employee benefits	83	(115)
- Changes in shareholders' equity reserves		
- Stock option reserve	178	132
- Reserve for translation adjustment from operating activities	(87)	(77)
- Change in other non-current assets/liabilities	(334)	(143)
Cash from operating activities before changes in working capital	28,653	19,040
(Increase)/Decrease in current receivables	(5,102)	(6,760)
(Increase)/Decrease in inventories	(4,112)	41
Increase/(Decrease) in trade payables	1,905	(1,337)
(Increase)/Decrease in other current items	(1,308)	(939)
Cash from operating activities	20,036	10,045
Income taxes paid	(1,540)	(1,273)
Interest paid	(434)	(611)
Net cash from operating activities	18,062	8,161
Investments in intangibles	(4,520)	(611)
Investments in property, plant and equipment	(4,586)	(2,423)
Retirements of property, plant and equipment	268	350
Cash used in investing activities	(8,838)	(2,684)
Repayment of loans	(173)	(164)
(Repayment of)/Proceeds from other borrowings	(518)	(393)
Effect of foreign exchange fluctuations	(122)	(193)
Cash used in financing activities	(813)	(750)
Net change in cash and cash equivalents	8,411	4,727
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	16,790	8,367
CASH AND CASH EQUIVALENTS AT END OF PERIOD	25,201	13,094

^(*) Unaudited data.

STATEMENT OF CHANGES IN CONSOLIDATED SHAREHOLDERS' EQUITY

(in thousands of euros)

	Share capital	Additional paid-in capital	Statutory reserve	Cumulative translation reserve	Stock option reserve	Retained earnings (Accumulated deficit)	Net result for the period	Group interest in shareholders' equity
Shareholders' equity at 12/31/2007	55,000	5,925	639	(2,790)	124	36,156	25,219	120,273
Appropriation of previous year's profit			501			24,718	(25,219)	
Dividend distribution						(5,500)		(5,500)
Share-based payments and other changes					592			592
Translation adjustment				1,323				1,323
Net result for the year							37,459	37,459
Shareholders' equity at 12/31/2008	55,000	5,925	1,140	(1,467)	716	55,374	37,459	154,147
Appropriation of previous year's profit								
Dividend distribution								
Share-based payments and other changes					178			178
Translation adjustment				2,589				2,589
Change in scope of consolidation						(145)		(145)
Net result for the period							13,161	13,161
Shareholders' equity at 3/31/2009 ^(*)	55,000	5,925	1,140	1,122	894	55,229	50,620	169,930

^(*) Unaudited data.

Notes to the consolidated financial statements at March 31, 2009

GENERAL INFORMATION AND SCOPE OF CONSOLIDATION

General information

The Diasorin Group is specialized in the development, manufacture and distribution of products in the immunochemistry and infectious immunology product groups. These product classes can also be grouped into a single family called immuno-diagnostics. Diasorin S.p.A., the Group's Parent Company, has its headquarters on Via Crescentino (no building number), in Saluggia (VC) 13040.

Principles for the preparation of the quarterly report

The consolidated quarterly report of the Diasorin Group at March 31, 2009 was prepared in accordance with the requirements of the relevant international accounting standard (IAS 34 – Interim Financial Reporting). These notes provide information in summary form, in order to avoid duplicating information published previously, as required by IAS 34. Specifically, these notes discuss only those components of the income statement and balance sheet the composition or change in amount of which require comment (due to the amount involved or the type of transaction or because an unusual transaction is involved) in order to understand the Group's operating performance, balance sheet and financial position.

The accounting principles applied to prepare the consolidated quarterly report are consistent with those used for the annual consolidated financial statements at December 31, 2008, since it has been determined that the revisions and interpretations published by the IASB that were applicable as of January 1, 2009 did not require any material changes in the accounting principles adopted by the Group the previous year.

When preparing interim financial statements, management is required to develop estimates and assumptions that affect the amounts shown for revenues, expenses, assets and liabilities in the financial statements and the disclosures provided with regard to contingent assets and liabilities on the date of the interim financial statements. If such estimates and assumptions, which were based on management's best projections, should differ from actual events, they will be modified appropriately when the relevant events produce the abovementioned differences.

Moreover, certain valuation processes, particularly the more complex processes such as determining whether the value of non-current assets has been impaired, are carried out fully only in connection with the preparation of the annual financial statements, when all necessary information is available, except when there are impairment indicators that require an immediate measurement of any impairment losses that may have occurred.

The Group engages in activities that, taken as a whole, are not subject to significant seasonal or cyclical shifts in revenue generation during the year.

The income tax liability is recognized using the best estimate of the weighted average tax rate projected for the entire year.

In this consolidated quarterly report, all amounts are in euros and are rounded to the nearest thousand, unless otherwise stated.

This quarterly report was not audited.

Scope of consolidation

The consolidated quarterly report includes the financial statements of Diasorin S.p.A., the Group's Parent Company, and those of its subsidiaries.

The scope of consolidation changed compared with December 31, 2008 due to the consolidation of the Diasorin Canada and Diasorin Czech subsidiary. Overall, the impact of the abovementioned change in scope of consolidation was not material.

Subsidiaries are companies over which the Group is able to exercise control, i.e., it has the power to, directly or indirectly, govern their operating and financial powers so as to obtain benefits from the results of their operations.

Subsidiaries are consolidated line by line from the date the Group obtains control until the moment when control ceases to exist. Dormant subsidiaries and subsidiaries that generate an insignificant volume of business are not consolidated. Their impact on the Group's total assets and liabilities, financial position and bottom-line result is not material.

A list of the subsidiaries included in the scope of consolidation, complete with information about head office locations and the percentage interest held by the Group, is provided in Annex I.

Other information

Information about significant events occurring after September 30, 2008, the Group's business outlook and its transactions with related parties is provided in separate sections of this Quarterly Report.

The table below shows the exchange rates used to translate amounts reported by companies that operate outside the euro zone:

Currency	Average		Actual	
	First quarter 2009	First quarter 2008	3/31/2009	3/31/2008
U.S. dollar	1.3029	1.4976	1.3308	1.3917
Brazilian real	3.0168	2.6012	3.0767	3.2436
British pound	0.9088	0.7570	0.9308	0.9525
Swedish kronor	10.9410	9.3996	10.9400	10.8700
Czech koruna	27.6008	25.5639	27.3880	26.8750
Canadian dollar	1.6223	1.5022	1.6685	1.6998
Mexican peso	18.7267	16.1862	18.7623	19.2333
Israeli shekel	5.2870	5.4322	5.5715	5.2780

	ITALY		EUROPE		UNITED STATES		REST OF THE WORLD		ELIMINATIONS		CONSOLIDATED	
<i>(in thousands of euros)</i>	3/31/2008	3/31/2009	3/31/2008	3/31/2009	3/31/2008	3/31/2009	3/31/2008	3/31/2009	3/31/2008	3/31/2009	3/31/2008	3/31/2009
INCOME STATEMENT												
Revenues from outsiders	20,319	20,083	17,951	22,629	14,302	22,979	4,318	5,678	(252)	-	56,638	71,369
Inter-segment revenues	11,612	15,924	2,811	4,497	2,353	3,971	-	-	(16,776)	(24,392)	-	-
Total revenues	31,931	36,007	20,762	27,126	16,655	26,950	4,318	5,678	(17,028)	(24,392)	56,638	71,369
Segment result	5,722	6,464	2,381	4,252	7,214	14,079	267	572	98	(962)	15,682	24,405
Unallocated common costs	-	-	-	-	-	-	-	-	-	-	-	-
EBIT	-	-	-	-	-	-	-	-	-	-	15,682	24,405
Other income (expense), net	-	-	-	-	-	-	-	-	-	-	-	-
Financial income (expense)	-	-	-	-	-	-	-	-	-	-	579	(3,640)
Result before taxes	-	-	-	-	-	-	-	-	-	-	16,261	20,765
Income taxes	-	-	-	-	-	-	-	-	-	-	(6,120)	(7,604)
Net result	-	-	-	-	-	-	-	-	-	-	10,141	13,161
OTHER INFORMATION												
Amortization	(368)	(362)	(46)	(500)	(50)	(69)	(24)	(47)	-	-	(488)	(978)
Depreciation	(1,275)	(1,287)	(1,061)	(1,121)	(369)	(467)	(610)	(548)	294	430	(3,021)	(2,993)
Total amortiz. and depreciation	(1,643)	(1,649)	(1,107)	(1,621)	(419)	(536)	(634)	(595)	294	430	(3,509)	(3,971)
	ITALY		EUROPE		UNITED STATES		REST OF THE WORLD		ELIMINATIONS		CONSOLIDATED	
<i>(in thousands of euros)</i>	12/31/2008	3/31/2009	12/31/2008	3/31/2009	12/31/2008	3/31/2009	12/31/2008	3/31/2009	12/31/2008	3/31/2009	12/31/2008	3/31/2009
BALANCE SHEET												
Segment assets	122,106	129,320	79,618	86,086	75,262	80,265	16,999	17,367	(68,015)	(71,235)	225,970	241,803
Unallocated assets	-	-	-	-	-	-	-	-	-	-	38,747	47,157
Total assets	122,106	129,320	79,618	86,086	75,262	80,265	16,999	17,367	(68,015)	(71,235)	264,717	288,960
Segment liabilities	67,746	71,305	41,152	43,332	6,805	8,997	10,767	7,389	(60,623)	(62,873)	65,847	68,150
Unallocated liabilities	-	-	-	-	-	-	-	-	-	-	44,723	50,880
Shareholders' equity	-	-	-	-	-	-	-	-	-	-	154,147	169,930
Total liabilities and shareholders' equity	67,746	71,305	41,152	43,332	6,805	8,997	10,767	7,389	(60,623)	(62,873)	264,717	288,960

Description and main changes

CONSOLIDATED INCOME STATEMENT

The notes to the consolidated income statement are provided below. More detailed information about the components of the income statement is provided in the Report on Operations.

1. Net revenues

In the first quarter of 2009, net revenues, which are generated mainly through the sale of diagnostic kits, totaled 71,369,000 euros, or 26.0% more than in the same period last year. First-quarter revenues include equipment rentals and technical support revenues of 1,561,000 euros in 2009, compared with 1,208,000 euros in 2008.

2. Cost of sales

In the first quarter of 2009, the cost of sales amounted to 21,482,000 euros, compared with 20,054,000 euros in the first three months of 2008. The cost of sales includes 2,242,000 euros paid for royalties (1,524,000 euros in the first quarter of 2008), 1,425,000 euros in costs incurred to distribute products to end customers (1,209 euros in the first quarter of 2008) and 2,089,000 euros in depreciation of medical equipment held by customers (2,216,000 euros in the first three months of 2008).

3. Sales and marketing expenses

Sales and marketing expenses increased to 13,499,000 euros in the first quarter of 2009, up from 11,267,000 euros in the first three months of 2008. This item consists mainly of marketing costs incurred to promote and distribute Diasorin products, costs attributable to the direct and indirect sales force and the cost of the technical support offered together with the Group-owned equipment provided to customers in accordance with gratuitous loan contracts.

4. Research and development costs

The amount recognized in the first quarter of 2009 as research and development costs, which totaled 3,783,000 euros (3,089,000 euros in the same period in 2008), reflect all research and development outlays (including the costs incurred to register the products offered for sale and meet quality requirements) that were not capitalized, amounting to 3,638,000 euros (2,959,000 euros in the first three months of 2008), and the amortization of previously capitalized development costs, which amounted to 145,000 euros (130,000 euros in the first quarter of 2008). During the first three months of 2009, the Group capitalized new costs totaling 431,000 euros (527,000 euros in the same period last year).

5. General and administrative expenses

General and administrative expenses, which include expenses incurred for corporate management activities, accounting, Group finance and control, information technology, corporate organization, and insurance, totaled 7,782,000 euros in the first quarter of 2009, up from 6,358,000 euros in the same period in 2008.

6. Other operating income (expenses)

Net other operating expense amounted to 418,000 euros (net other operating expense of 188,000 euros in the first quarter of 2008). The balance in this account represents the net difference between other income from operations generated by transactions other than the sale of goods (e.g., gains on asset disposals, government grants, insurance settlements) and other operating expenses that cannot be allocated to specific functional areas (e.g., losses on asset disposals, out-of-period charges, indirect taxes and fees, additions to provisions for risks).

7. Net financial income (expense)

A breakdown of financial income and expense is provided below:

	First quarter 2009	First quarter 2008
Interest and other financial expense	(880)	(1,074)
Interest on pension funds	(34)	(66)
Interest and other financial income	34	62
Net translation adjustment	(2,760)	1,657
Net financial income (expense)	(3,640)	579

In the first quarter of 2009, net financial expense totaled 3,640,000 euros, as against net financial income of 579,000 euros in the same period the previous year. Interest and other financial expense includes 243,000 euros in interest paid on loans (224,000 euros in the first quarter of 2008), 324,000 euros in fees on factoring transactions (505,000 euros in the first quarter of 2008) and 216,000 euros in financial expense on employee benefit plans (223,000 euros in the first quarter of 2008).

8. Income taxes

The income tax expense recognized in the consolidated income statement for the first quarter of 2009 amounted to 7,604,000 euros (6,120,000 euros at March 31, 2008), equal to 36.6% of the result before taxes. The income tax rate was 37.6% in 2008.

9. Earnings per share

Basic earnings per share, which are computed by dividing the Group interest in net result by the average number of shares outstanding, amounted to 0.24 euros in the first quarter of 2009, up from 0.18 euros in the same period last year.

CONSOLIDATED BALANCE SHEET

10. Property, plant and equipment

The table below shows the changes that occurred in this account as of March 31, 2009:

<i>(in thousands of euros)</i>	12/31/2008	Additions	Depreciation	Retirements	Translation adjustment	Reclassifications and other changes	3/31/2009
Land	2,310	–	–	–	11	–	2,321
Buildings	6,836	7	190	–	136	25	6,814
Plant and machinery	3,784	82	185	–	11	78	3,770
Manufacturing and distribution equipment	18,948	3,883	2,472	(268)	241	317	20,649
Other property, plant and equipment	1,771	354	146	–	24	(10)	1,993
Construction in progress and advances	1,797	260	–	–	14	(425)	1,646
Total property, plant and equipment	35,445	4,586	2,993	(268)	437	(15)	37,193

11. Intangible assets

A breakdown of intangible assets at March 31, 2009 is as follows:

<i>(in thousands of euros)</i>	12/31/2008	Additions	Amortization	Translation adjustment	Reclassifications and other changes	3/31/2009
Goodwill	59,892	–	–	–	–	59,892
Development costs	9,882	431	145	54	–	10,222
Concessions, licenses and trademarks	8,065	3,389	307	22	401	11,570
Industrial patents and intellectual property rights	14,538	26	480	(44)	–	14,040
Advance and other intangibles	928	674	46	–	(386)	1,170
Total in tangibles	93,305	4,520	978	32	15	96,894

12. Inventories

A breakdown of inventories at March 31, 2009 and a comparison with the data at March 31, 2008 is as follows:

<i>(in thousands of euros)</i>	3/31/2009			12/31/2008		
	Gross amount	Provisions for write-downs	Net amount	Gross amount	Provisions for write-downs	Net amount
Raw materials and supplies	15,651	(1,522)	14,129	14,902	(1,276)	13,626
Work in progress	20,260	(1,721)	18,539	18,286	(1,652)	16,634
Finished goods	14,531	(1,197)	13,334	12,436	(1,253)	11,183
Total	50,442	(4,440)	46,002	45,624	(4,181)	41,443

13. Trade receivables

Trade receivables totaled 68,330,000 euros at March 31, 2009. As of the same date, the allowance for doubtful accounts amounted to 5,849,000 euros. The table below shows the changes that occurred in the allowance for doubtful accounts:

<i>(in thousands of euros)</i>	3/31/2009	12/31/2008
Opening balance	5,551	5,938
Additions for the period	227	448
Utilizations/reversals for the period	(36)	(389)
Currency translation differences and other changes	107	(446)
Ending balance	5,849	5,551

14. Shareholders' equity

Shareholders' equity totaled 169,930,000 euros at March 31, 2009. The increase of 15,783,000 euros is the net result of the earnings for the period (13,161,000 euros) and the effect of changes in foreign exchange rates on the translation of financial statements denominated in currencies other than the euro (2,589,000 euros). Consolidated gains and losses that are recognized directly in equity included the following:

<i>(in thousands of euros)</i>	3/31/2009	12/31/2008
Translation differences	2,589	1,323
Gains (Losses) recognized directly in equity	2,589	1,323
Stock option costs	178	592
Net result for the period	13,161	37,459
Total gains recognized during the reporting period	15,928	39,374

15. Borrowings

The table that follows lists the borrowings outstanding at March 31, 2009 and provides a comparison with the data at March 31, 2008 (amounts in thousands of euros).

Lending institution	Balance at 12/31/08	New borrowings during the period	Repayments during the period	Translation difference	Amortized cost effect	Balance at 3/31/09
Interbanca USD 2008	30,668	–	–	1,415	3	32,086
IMI/Italian Ministry of Education	1,022	–	–	–	12	1,034
Unicredit for flood relief	1,104	–	(173)	–	16	947
Leasing companies	3,759	5	(523)	–	–	3,241
Total	36,553	5	(696)	1,415	31	37,308

The table below provides a breakdown of borrowings by maturity (amounts in thousands of euros).

Lending institution	Currency	Short-term amount	Long-term amount	Amount due after 5 years	Total
Interbanca USD 2008	USD	4,300	38,379	4,330	42,679
	Amount in EUR	2,748	29,338	3,209	32,086
IMI/Italian Ministry of Education	EUR		1,034	431	1,034
Unicredit for flood relief	EUR	362	585		947
Leasing companies	EUR	1,759	1,482	–	3,241
Total		4,869	32,439	3,640	37,308

16. Provision for employee severance indemnities and other employee benefits

The liability for employee benefit plans totaled 19,461,000 euros at March 31, 2009. The table that follows provides a breakdown of the changes that occurred in the first quarter of 2009:

<i>(in thousands of euros)</i>	Defined-benefit plans	Other benefits	Total employee benefits
Balance at December 31, 2008	18,245	1,061	19,306
Financial expense/(income)	211	5	216
Actuarial losses/(gains)	(15)	11	(4)
Service costs	55	44	99
Contribution/Benefits paid	(133)	(12)	(145)
Currency translation differences and other changes	(10)	(1)	(11)
Balance at March 31, 2009	18,353	1,108	19,461

17. Other non-current liabilities

The balance in this account, which amounted to 2,113,000 euros at March 31, 2009, includes non-current liabilities of 297,000 euros and provisions for risk and charges totaling 1,816,000 euros. The table below shows the changes in these provisions:

<i>(in thousands of euros)</i>	3/31/2009	12/31/2008
Opening balance	1,594	2,239
Additions for the period	200	435
Utilizations	(5)	(290)
Reversals for the period	(27)	(607)
Currency translation differences and other changes	54	(183)
Ending balance	1,816	1,594

Annex I: List of Equity Investments

Company	Head office location	Currency	Share capital	Par value per share or partnership interest	% interest held directly	Number of shares held
Diasorin S.A/N.V.	Brussels (Belgium)	EUR	1,674,000	6,696	99.99%	249
Diasorin Ltda	São Paulo (Brazil)	BRR	10,011,893	1	99.99%	10,011,892
Diasorin S.A.	Antony (France)	EUR	960,000	15	99.99%	62,494
Diasorin Iberia S.A.	Madrid (Spain)	EUR	1,453,687	6	99.99%	241,877
Diasorin Ltd	Wokingham (Great Britain)	GBP	500	1	100.00%	500
Diasorin Inc.	Stillwater (United States)	USD	1	0.01	100.00%	100
Diasorin Canada Inc.	Vancouver (Canada)	CAD	200,000	N/A	100.00%	100 Class A Common shares
Diasorin Mexico S.A de C.V.	Mexico City (Mexico)	MXP	100,000	1	99.99%	99,999
Diasorin Deutschland GmbH	Dietzenbach (Germany)	EUR	275,000	1	100.00%	1
Diasorin AB	Sundbyberg (Sweden)	SEK	5,000,000	100	100.00%	50,000
Diasorin Ltd	Rosh Haayin (Israel)	ILS	100	1	100.00%	100
Diasorin Austria GmbH	Vienna (Austria)	EUR	35,000	35,000	100.00%	1
Diasorin Czech S.ro.	Prague (Czech Republic)	CZK	200,000	200,000	100.00%	1
Biotrin Group Limited	Dublin (Ireland)	EUR	3,922.82	0.01	100.00%	392,282
Biotrin Holdings Limited	Dublin (Ireland)	EUR	7,826,072	0.01	100.00%	782,607,110
Biotrin International Limited	Dublin (Ireland)	EUR	193,041	0.12	100.00%	1,608,672
Biotrin Limited	Dublin (Ireland)	EUR	120	1.2	100.00%	100,000
Biotrin Technologies Limited	Dublin (Ireland)	EUR	163,202	1.2	100.00%	136,002
Biotrin Intellectual Properties Limited	Dublin (Ireland)	EUR	144	0.6	97.00%	233
Biotrin Intellectual Property Holdings Limited	Dublin (Ireland)	EUR	100	1	100.00%	98 Preferred Shares 1 Ordinary Share 1 Deferred Share
Equity Investments Valued at Cost						
Diasorin Ltd	Shanghai (China)	EUR	120,000	1	80.00%	96,000
Byk Sangtec Diagnostica Unterstuetzungskasse GmbH	Dietzenbach (Germany)	EUR	25,565	1	100.00%	1
Equity Investments in Other Companies						
Consorzio Sobedia	Saluggia (Italy)	EUR	5,000		20.00%	1

**Declaration in accordance with the second subsection of Art. 154-*bis*, Part IV,
Title III, Second Paragraph, Section V-*bis*, of Legislative Decree No. 58
of February 24, 1998: "Uniform Law on Financial Intermediation Enacted
Pursuant to Articles 8 and 21 of Law No. 52 of February 6, 1996"**

I, the undersigned, Andrea Senaldi, Officer Responsible for the preparation of corporate financial reports of Diasorin S.p.A.

ATTEST

as required by the second subsection of Art. 154-*bis*, Part IV, Title III, Second Paragraph, Section V-*bis*, of Legislative Decree No. 58 of February 24, 1998, that, to the best of my knowledge, the financial information included in the present document corresponds to book of accounts and bookkeeping entries of the Company.

Andrea Senaldi

Officer Responsible for the preparation
of corporate financial reports
DIASORIN S.p.A.



The Diagnostic Specialist

Via Crescentino snc - 13040 Saluggia (VC)